Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #2813091

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	4 206 EUR	4 206 EUR	—	5 822 EUR	5 822 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions	—	—	119,000 EUR	—	—	49,000 EUR
Adjustments for share-based payments	—	—	506,000 EUR	—	—	815,000 EUR
Other adjustments for non-cash items	—	—	- EUR	—	—	10,000 EUR
Cash flows from (used in) operations	—	—	3 456 EUR	—	—	4 948 EUR
Income taxes paid (refund), classified as operating activities	—	—	- EUR	—	—	- EUR
Cash flows from (used in) operating activities	—	—	3 359 EUR	—	—	6 692 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	—	- EUR	—	—	3,000 EUR
Purchase of property, plant and equipment, classified as investing activities	—	—	165,000 EUR	—	—	166,000 EUR
Proceeds from sales of intangible assets, classified as investing activities	—	—	- EUR	—	—	- EUR
Purchase of intangible assets, classified as investing activities	—	—	10,000 EUR	—	—	- EUR
Cash flows from (used in) investing activities	—	—	175,000 EUR	—	—	1 338 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	—	- EUR	—	—	4 056 EUR
Repayments of borrowings, classified as financing activities	—	—	236,000 EUR	—	—	19,000 EUR
Cash flows from (used in) financing activities	—	—	194,000 EUR	—	—	3 972 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	—	- EUR	—	—	- EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	—	3 728 EUR	—	—	1 382 EUR
Cash and cash equivalents	4 046 EUR	—	—	7 935 EUR	—	—